Ftse Mib
35.323,14
0,49%
DAX
18.788,29
0,35%
S&P 500
5.246,68
0,48%
NASDAQ
16.511,18
0,75%
Bitcoin
62.095,20
0,89%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TransCode Therapeutics Inc (RNAZ) TransCode Therapeutics Inc (RNAZ) Notizie

TransCode Therapeutics Inc

RNAZ
0,77
0,0399 (5,47%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/5/202423:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/5/202414:30GLOBETransCode Therapeutics Open Letter to Shareholders
10/5/202422:50EDGAR2Form PRE 14A - Other preliminary proxy statements
10/5/202422:45EDGAR2Form 8-K - Current report
15/4/202415:00GLOBETransCode Therapeutics Announces FDA Clearance To Initiate..
03/4/202415:10GLOBETransCode Therapeutics Reports 2023 Results; Provides..
28/3/202413:30GLOBETransCode Therapeutics Announces Appointment of Daniel..
11/3/202414:00GLOBETransCode Therapeutics and Akribion Genomics Report Progress..
06/3/202422:15GLOBETransCode Therapeutics To Present At 2024 RNA Leaders Europe..
20/2/202414:00GLOBETransCode Therapeutics Reports Publication of United States..
15/2/202422:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202402:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202422:33EDGAR2Form 8-K - Current report
31/1/202422:05GLOBENasdaq Determines TransCode Therapeutics Compliance with..
29/1/202414:30GLOBETransCode Therapeutics and Debiopharm Announce Collaboration..
22/1/202422:45EDGAR2Form 8-K - Current report
22/1/202422:45GLOBETransCode Therapeutics Announces Closing of $7.25 Million..
20/1/202403:57EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
19/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
18/1/202419:27GLOBETransCode Therapeutics Announces Pricing of $7.25 Million..
18/1/202416:39EDGAR2Form S-1/A - General form for registration of securities..
17/1/202413:06EDGAR2Form S-1/A - General form for registration of securities..
16/1/202422:01EDGAR2Form 8-K - Current report
12/1/202422:05GLOBETransCode Therapeutics Reports Further Restructuring to..
11/1/202414:22EDGAR2Form S-1 - General form for registration of securities under..
11/1/202414:00GLOBETransCode Therapeutics Announces 1-for-40 Reverse Stock..
08/1/202422:01EDGAR2Form 8-K - Current report
04/1/202418:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/1/202414:05GLOBETransCode Therapeutics Publishes Open Letter Outlining..
18/12/202322:28EDGAR2Form DEF 14A - Other definitive proxy statements
12/12/202314:30GLOBETransCode Therapeutics Reports Positive Pre-Clinical Results..
08/12/202322:57EDGAR2Form PRE 14A - Other preliminary proxy statements
08/12/202322:56EDGAR2Form 8-K - Current report
07/12/202322:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/12/202315:00GLOBETransCode Therapeutics To Present Phase 0 Data at 2023 San..
04/12/202323:07EDGAR2Form 8-K - Current report
04/12/202322:10GLOBETransCode Therapeutics Announces Closing of $1.2 Million..
01/12/202323:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/11/202320:53GLOBETransCode Therapeutics Announces $1.2 Million Registered..
14/11/202322:40EDGAR2Form 8-K - Current report
14/11/202322:30GLOBETransCode Therapeutics Reports Third Quarter 2023 Results;..
09/11/202322:13EDGAR2Form 8-K - Current report
01/11/202303:20APSBiotech Shares Bid Up Following Public Offering Cancellation
30/10/202321:33GLOBETransCode Therapeutics Withdraws Public Offering
27/10/202322:06EDGAR2Form 8-K - Current report
27/10/202314:00GLOBENasdaq Panel Grants TransCode Therapeutics Extension for..
26/10/202322:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/10/202322:19GLOBETransCode Therapeutics Announces Public Offering of Common..
26/10/202314:00GLOBETransCode Therapeutics Announces Prolonged Survival in..
24/10/202314:05EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 0,7301

La tua Cronologia

NASDAQ
RNAZ
TransCode Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network